OPTASE®

OMEGA VISION





A High EPA & DHA Omega-3 Supplement for Dry Eye Disease, Blepharitis & MGD









MGD* has been shown to be the leading cause of Dry Eye Disease and Blepharitis.¹



In a clinical study of Dry Eye Disease patients, **9 out of 10** individuals were shown to suffer from the evaporative form of DED.²



MGD has been shown in population-based studies to have a **prevalence of up to 69%** in patients over the age of 40.1



Dietary supplementation with omega-3 fatty acids have been recommended as **primary therapy** for DED, Blepharitis and MGD.^{1,3}



8 in 10 practices refer patients to High Street Omega 3 suppliers.⁴

*Meibomian Gland Dysfunction (MGD)



MGD is associated with altered lipid composition which contributes to evaporative DED¹

Typically MGD Patients Experience a Cycle of Inflammation.





Decrease in lipid secretion



Leads to tear film instability



Inflammation, itching,

Ocular surface exposure to allergens like dust, pollen and animal hair



Increase in evaporation



The Role of Omega-3 in MGD

Omega-3 and Omega-6 fatty acids are essential to good health but cannot be synthesized by the body and so they must be obtained from the diet.

Both essential fatty acids (EFA) have a role in to play. Omega 6's are pro-inflammatory whereas Omega 3's have anti-inflammatory properties. For general health, there needs to be a balance.





Omega Imbalance (excess Omega-6:Omega-3)

- causes the meibum to become thick, viscous and inflamed⁶
 - causes the Meibomian Glands to become blocked⁶
 - prevents the production of the lipid layer⁶


Without the lipid layer, the aqueous layer evaporates, causing the ocular surface to become irritated (red, dry, scratchy, i.e. dry eye)



The proven benefits of Omega-3 in improving symptoms of Dry Eye Disease

- In Clinical Studies, doses of 360mg EPA and 220mg DHA have demonstrated beneficial effects in alleviating DED symptoms.^{7,8}
- Taking Omega-3 supplements may help produce a more uniform lipid layer resulting in a restored tear film and decrease in evaporation.⁷

OPTASE® Omega Vision



1g Omega-3 (EPA and DHA)

2 softgels daily deliver an effective dry eye dose.^{7,8}



Supplementing the diet with 1g of Omega-3 EPA and DHA7:

✓ Improves Tear Break Up Time by 71%
✓ Decreases OSDI* by 26%

✓ Increases Schirmer's Score by 22%

*Ocular Surface Disease Index (a commonly used tool for diagnosing dry eye disease)



Specialised Manufacturing

OPTASE® Omega Vision has been manufactured using a specialised process to deliver a **re-esterified Triglyceride** (**rTG**) form of Omega-3 fish oil which studies have shown to have **higher bioavailability*** and **better absorption** than the Ethyl Ester form of Omega-3 oil.9

*Bioavailability refers to the proportion of a dose that reaches the systemic circulation after its administration



The manufacturing process:



Fish are pressed, producing unpurified (Triglyceride) Omega-3 oil



The oil is purified using heat and alcohol (esterification)



Purified Omega-3 oil is produced which now contains alcohol. This Ethyl Ester form of Omega-3 oil is poorly absorbed by the body⁶



The alcohol is removed through re-esterification



OPTASE® Omega Vision is purified, free of alcohol and toxins, and contains high levels of EPA & DHA





What this means for your patient?

- High EPA and DHA levels benefit eye health
- Specialised manufacturing process provides optimum absorption Omega-3 oil
- Absence of alcohol means OPTASE® Omega Vision leaves no fishy or unwanted aftertaste
- Taking 2 softgels daily delivers an effective dry eye dose





Best Practice Eye Care Regime³

HEAT

CLEANSE

HYDRATE



Heat Mask





With OPTASE® Tea Tree Oil Lid Wipes



With **OPTASE®** Eye Spray or **Hycosan®** Eye Drops

SUPPLEMENT



With OPTASE® Omega Vision

Product Overview

OPTASE® OMEGA VISION	FEATURES (Per serving size: 2 softgels)
Presentation	60 softgels in Blister Packs
Composition	600mg EPA, 400mg DHA, 200mg other omega 3 fatty acids
Recommended Use	DED, Blepharitis, MGD
Supply	30-day supply

References:

- Geerling G et al. The International Workshop on Meibomian Gland Dysfunction: Report on the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. 2011 Mar; 52(4): 2050–2064.
- Lemp MA et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient population. Cornea. 2012 May;31(5):472-8
- TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. Epub 2017 Jul 20
- 4. Scope Research. Data on file 2017
- Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016;8(3):128. doi:10.3390/ nu8030128.
- Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-56.
- Kangari H et al. Short-term Consumption of Oral Omega-3 and Dry Eye Syndrome. Ophthalmology. 2013 Nov;120(11):2191-6. doi: 10.1016/j. ophtha.2013.04.006. Epub 2013 May 1
- Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea. 2015 Apr;34(4):413-20. doi: 10.1097/ ICO.0000000000000386
- Dyerburg J, et al. Bioavailability of marine n-3 acid formulations, Prostaglandins Leukotrines Essent Fatty Acids 2010, doi10.1016/j. plefa.2010.06.007.6



OPTASE® OMEGA VISION

